SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin.

Abstract	We identified four breast cancer cell lines and one stomach cancer cell line resistant to the cytotoxic effects of doxorubicin (DOX) and examined their sensitivity to other chemotherapeutic agents. SP600125, an inhibitor of the Jnk pathway, reduced the cellular viability of all five DOX-resistant cancer cell lines. Jnk1 siRNA also reduced the viability of the one DOX-resistant cell line in which it was tested. Similar results were produced in an in vivo mouse model, in which the volume of tumors derived from the DOX-resistant cell line was reduced more effectively by treatment with SP600125 than by treatment with DOX, whereas those from a DOX-sensitive cell line were reduced only by DOX treatment. Overall, these results may contribute to the development of chemotherapeutic treatments for patients with DOX-resistant tumors.
Authors	Ju-Hwa Kim, Tae Hyung Kim, Han Sung Kang, Jungsil Ro, Hyung Sik Kim, Sungpil Yoon
Journal	Biochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 387 Issue 3 Pg. 450-5 (Sep 25 2009) ISSN: 1090-2104 [Electronic] United States
PMID	19607816 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Anthracenes Antineoplastic Agents Protein Kinase Inhibitors RNA, Small Interfering pyrazolanthrone Doxorubicin JNK Mitogen-Activated Protein Kinases Mitogen-Activated Protein Kinase 8
Topics	Animals Anthracenes (pharmacology) Antineoplastic Agents (pharmacology) Breast Neoplasms (enzymology) Cell Line, Tumor Cell Survival (drug effects) Doxorubicin (pharmacology) Drug Resistance, Neoplasm (drug effects) Female Humans JNK Mitogen-Activated Protein Kinases (antagonists & inhibitors, genetics) Mice Mitogen-Activated Protein Kinase 8 (antagonists & inhibitors, genetics) Protein Kinase Inhibitors (pharmacology) RNA, Small Interfering (genetics) Stomach Neoplasms (enzymology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!